ALBUQUERQUE, N.M., Nov. 19 /PRNewswire-FirstCall/ -- Biomoda, Inc. (http://www.biomoda.com) of Albuquerque, NM, announced today Dr. Leo Gomez has joined Biomoda as Director of Research, spearheading the company’s research efforts towards commercialization of its assay for the early detection of lung cancer.
Dr. Gomez has coordinated and managed more than 30 medical device, radiopharmaceutical and nuclear research projects over his thirty-year career as a nationally respected senior scientist. Most recently, as Director of Research for TCI Medical headquartered in Albuquerque, Dr. Gomez coordinated research and clinical trials on medical innovations among scientific institutions in the former Soviet Union and the U.S. He worked as a senior scientist at the U.S. Department of Energy’s Sandia National Laboratories, Los Alamos National Laboratory and Oak Ridge National Laboratory for twenty-eight years, and was editor of an international environmental journal for more than ten years. The author of numerous articles, Dr. Gomez also served on more than 40 National Technical Review Boards, Advisory Boards and the Board of Directors of scientific, educational and professional organizations.
“Dr. Gomez brings an exceptionally well-suited approach to scientific study and the commercial development of medical breakthroughs such as our early lung cancer detection assay,” said John Cousins, President of Biomoda. “His experience and expertise with clinical trials and knowledge and skill with publications will be put to excellent use. Biomoda is poised to begin a myriad of projects that Dr. Gomez directs. His experience will be invaluable.”
Dr. Gomez was awarded a Masters of Science in Radiation Biology and Health Physics and a Ph.D. in Radiation Biology from Colorado State University. He holds a Bachelor of Science degree from the University of New Mexico
Biomoda’s patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.
Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.
Contact: John Cousins (505) 821-0875
CONTACT: John Cousins of Biomoda, Inc., +1-505-821-0875
Web site: http://www.biomoda.com/
